NRX Pharmaceuticals (NRXP) Gross Margin (2025 - 2026)

NRX Pharmaceuticals' (NRXP) quarterly Gross Margin came in at 40.92% in Q1 2026, down 28.73% on a QoQ basis from 57.41% in Q4 2025.

NRX Pharmaceuticals (NRXP) Gross Margin (2025 - 2026) Analysis & Trends

NRX Pharmaceuticals (NRXP) has 2 years of Gross Margin data on file, last reported at 40.92% in Q1 2026.

On a quarterly basis, Gross Margin changed N/A year-over-year to 40.92% in Q1 2026; TTM through Mar 2026 was 48.97%, a N/A change from a year earlier, with the FY2025 full-year figure at 57.92%, changed N/A from the prior year.
Gross Margin for Q1 2026 stood at 40.92%, down from 57.41% in the prior quarter.
Over the last five years, Gross Margin for NRXP reached as high as 57.41% in Q4 2025 and fell as low as 40.92% in Q1 2026.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Gross Margin (Qtr)
1	Oculis Holding AG	67,222.41 Bn	67,222.13 Bn	-	-
2	Nanobiotix	1,909.44 Bn	1,909.38 Bn	-	-
3	Akari Therapeutics	989.71 Bn	989.71 Bn	-	-
4	BeOne Medicines	472.06 Bn	467.27 Bn	1.35 Bn	88.95%
5	Vertex Pharmaceuticals	122.10 Bn	114.85 Bn	2.59 Bn	86.85%
6	Regeneron Pharmaceuticals	70.00 Bn	61.25 Bn	3.31 Bn	91.79%
7	Belite Bio	62.68 Bn	62.68 Bn	-	-
8	Argenx Se	55.75 Bn	50.57 Bn	1.41 Bn	90.68%
9	Alnylam Pharmaceuticals	37.50 Bn	34.50 Bn	959.66 Mn	82.22%
10	NRX Pharmaceuticals	116.33 Mn	109.63 Mn	437,000.00	40.92%

Historic Data

Download Data

Date	Value
Mar 31, 2026	40.92%
Dec 31, 2025	57.41%
Sep 30, 2025	51.50%